|
Accession Number
|
ADA566405
|
|
Title
|
Production and Characterization of a Novel OX40 Ligand for Clinical Use.
|
|
Publication Date
|
Aug 2012
|
|
Media Count
|
12p
|
|
Personal Author
|
A. D. Weinberg
|
|
Abstract
|
The goals of the second year/phase of the DOD funded research, PC073499, have been accomplished. We produced two human versions of the OX40 ligand:trimer:Ig protein. The two protein constructs have different human trimer domains (TRAF2 and Matrillin-4), which confer differing folding patterns within the two-dimension structure of the protein. These two fully human OX40L:Ig fusion proteins were administered to non-human primates to test for in vivo activity. The OX40L:Ig fusion proteins showed potent biologic activity in vivo, but it was clear that the one with the TRAF2 trimer domain was superior. Therefore we are moving forward with OX40L:Ig fusion protein with the TRAF2 trimer domain with the ultimate hope of taking it to clinical trials in patients with prostate cancer.
|
|
Keywords
|
Cells(Biology)
Clinical medicine
Clinical trials
Co-stimulation
Histology
Hosts(Biology)
In vivo analysis
Ox40
Potency
Primates
Prostate cancer
Proteins
T lymphocytes
Tissues(Biology)
Tumor immunotherapy
|
|
|
Source Agency
|
Non Paid ADAS
|
|
NTIS Subject Category
|
57E - Clinical Medicine
|
|
Corporate Author
|
Angov (Evelina), Bethesda, MD.
|
|
Document Type
|
Technical report
|
|
Title Note
|
Final rept. 15 Jul 2008-14 Jul 2012.
|
|
NTIS Issue Number
|
1307
|
|
Contract Number
|
W81XWH-08-1-0436
|
